Friday, July 10, 2026

pharma · Ependymoma, Medulloblastoma · chronically occluded coronary artery

Ishita Pharma -

Ishita Pharma - clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Mumbai, IN HQ
3 Employees
EMA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Employees
3
Programs
8
Drugs
19
Patents
0
Intelligence · Clinical Programs

Ishita Pharma - projects

7 ClinicalTrials.gov programs sponsored by Ishita Pharma -.

Ishita Pharma - has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AUTOP 2

    ISTA Pharma Limited

    Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities

    phase 3 small molecule active

    1 trial
  2. Etude DAPT-CTO

    ISTA Pharma Limited

    chronically occluded coronary artery

    phase 3 small molecule active

    1 trial
  3. KVD900 150 mg

    ISTA Pharma Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial
  4. MICROPREP III

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial
  5. NICOTINAMIDE, cellulose microcristalline

    ISTA Pharma Limited

    Acute kidney injury

    phase 3 small molecule active

    1 trial
  6. RCAPHM18_0018

    ISTA Pharma Limited

    Hirschsprung's disease

    phase 3 small molecule active

    1 trial
  7. RCAPHM19_0374

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Ishita Pharma - have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.